Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma
Jessica C. Hassel, Sophie Piperno‐Neumann, Piotr Rutkowski, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 24, pp. 2256-2266
Open Access | Times Cited: 93

Showing 1-25 of 93 citing articles:

Tebentafusp, a T cell engager, promotes macrophage reprogramming and in combination with IL-2 overcomes macrophage immunosuppression in cancer
Esra Güç, Agatha Treveil, Emma Leach, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 2
15-Gene Expression Profile and PRAME as Integrated Prognostic Test for Uveal Melanoma: First Report of Collaborative Ocular Oncology Group Study No. 2 (COOG2.1)
J. William Harbour, Zélia M. Corrêa, Amy C. Schefler, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 28, pp. 3319-3329
Open Access | Times Cited: 15
Bispecific antibodies: advancing precision oncology
M. Zurita Herrera, G. Pretelli, Jayesh Desai, et al.
Trends in cancer (2024) Vol. 10, Iss. 10, pp. 893-919
Open Access | Times Cited: 15
Uveal melanoma: Current evidence on prognosis, treatment and potential developments
Maria C. Gelmi, Martine J. Jager
Asia-Pacific Journal of Ophthalmology (2024) Vol. 13, Iss. 2, pp. 100060-100060
Open Access | Times Cited: 12
Current State of Melanoma Therapy and Next Steps: Battling Therapeutic Resistance
Anna Fateeva, Kevinn Eddy, Suzie Chen
Cancers (2024) Vol. 16, Iss. 8, pp. 1571-1571
Open Access | Times Cited: 12
A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal Melanoma
Elizabeth I. Buchbinder, Justine V. Cohen, Giuseppe Tarantino, et al.
Cancer Research Communications (2024) Vol. 4, Iss. 5, pp. 1321-1327
Open Access | Times Cited: 12
Beyond Chemoimmunotherapy in Advanced Non–Small Cell Lung Cancer: New Frontiers, New Challenges
Giannis Mountzios, Jarushka Naidoo, Chao Wang, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 11
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2024
Claus Garbe, Teresa Amaral, Ketty Peris, et al.
European Journal of Cancer (2024) Vol. 215, pp. 115153-115153
Open Access | Times Cited: 9
Non-Cutaneous Melanoma
Leanne Brown, Kelly Olino
Surgical Oncology Clinics of North America (2025)
Closed Access | Times Cited: 1
Optimizing TIL therapy for uveal melanoma: lessons learned and unlearned from cutaneous melanoma
Shravan Leonard‐Murali, Udai S. Kammula
Immunotherapy (2025), pp. 1-9
Open Access | Times Cited: 1
Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma
Joseph J. Sacco, Richard D. Carvajal, Marcus O. Butler, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 6, pp. e009028-e009028
Open Access | Times Cited: 6
T Cell-Engaging Bispecific Antibodies Targeting gp100 and PRAME: Expanding Application from Uveal Melanoma to Cutaneous Melanoma
Robin Reschke, Alexander Enk, Jessica C. Hassel
Pharmaceutics (2024) Vol. 16, Iss. 8, pp. 1046-1046
Open Access | Times Cited: 6
Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis
Josep M. Piulats, Claire Watkins, Marcel Costa-García, et al.
Annals of Oncology (2023) Vol. 35, Iss. 3, pp. 317-326
Open Access | Times Cited: 16
Detection of neoplastic-immune hybrid cells with metastatic properties in uveal melanoma
Ashley N. Anderson, Patrick T. Conley, Christopher Klocke, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 5
Updates in the Management of Uveal Melanoma
Mali Barbi, Richard D. Carvajal, Craig Devoe
The Cancer Journal (2024) Vol. 30, Iss. 2, pp. 92-101
Closed Access | Times Cited: 4
Advances in Vaccines for Melanoma
Can Cui, Patrick A. Ott, Catherine J. Wu
Hematology/Oncology Clinics of North America (2024) Vol. 38, Iss. 5, pp. 1045-1060
Closed Access | Times Cited: 4
Identification of lncRNA-miRNA-mRNA ceRNA axes and KEGG pathways related to uveal melanoma metastasis
Zhiyun Zhan, Huilong Chen, Ting Wang, et al.
Technology and Health Care (2025)
Closed Access
Selinexor (KPT-330) in Combination with Immune Checkpoint Inhibition in Uveal Melanoma: A Phase 1B Trial
Mohamed A. Gouda, Abdulrazzak Zarifa, Yali Yang, et al.
Journal of Immunotherapy and Precision Oncology (2025) Vol. 8, Iss. 1, pp. 82-88
Open Access
An Optimized NGS Workflow Defines Genetically Based Prognostic Categories for Patients with Uveal Melanoma
Michele Massimino, Elena Tirrò, Stefania Stella, et al.
Biomolecules (2025) Vol. 15, Iss. 1, pp. 146-146
Open Access
Extracellular vesicles in uveal melanoma - biological roles and diagnostic value
Ornella Urzì, Roger Olofsson Bagge, Rossella Crescitelli
Cancer Letters (2025), pp. 217531-217531
Closed Access
Characterizing uveal melanoma patients with peritoneal metastases: a retrospective single-center analysis
Stanislav Rosnev, Caroline Anna Peuker, Iris Piwonski, et al.
European Journal of Cancer (2025) Vol. 218, pp. 115280-115280
Open Access
Clinical and Proteomic Insights into a Cytokine Release Syndrome Triggered by Tebentafusp in a Metastatic Uveal Melanoma Patient: Case Report
Antonio David Lazaro Sanchez, Javier David Benítez Fuentes, Ginés Luengo‐Gil, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 4, pp. 1333-1333
Open Access
The Full‐Length Genomic Sequence of the HLA‐A*02:07:08 Allele
Wei Tian, Lixin Li
HLA (2025) Vol. 105, Iss. 3
Closed Access
Increasing Incidence of Posterior Uveal Melanoma in Scandinavia 1960–2022: A Tri-National Study
Kristoffer Nissen, Jens Folke Kiilgaard, Maria Filì, et al.
American Journal of Ophthalmology (2025)
Closed Access
Surveillance for Metastasis in Low-Risk Uveal Melanoma Patients: Need for Optimization
Alexander R. Delaney, Yağmur Seda Yeşiltaş, Emily C. Zabor, et al.
Ophthalmology (2025)
Open Access
Page 1 - Next Page

Scroll to top